CLL

Autoimmune diseases in patients with CLL are separate from CLL, which calls for different treatments.

After receiving two cancer diagnoses, I became more vigilant about my health — especially during the COVID-19 pandemic.

Fewer patients with chronic lymphocytic leukemia experienced cardiac toxicities with Calquence than those treated with Imbruvica, research showed.

Never underestimate your value to a person who has just been diagnosed. Isn’t that what these blogs are all about anyway?

CURE looks back on some of the most important stories in the chronic lymphocytic leukemia space from 2023.

Patients with chronic lymphocytic leukemia treated with Imbruvica plus Venclexta demonstrated a healthy immune profile over time in addition to reduction in CLL disease burden.

Geoff Grubbs, who was diagnosed with chronic lymphocytic leukemia in 2009, has undergone five lines of treatment and participated in two clinical trials.

After being told, "You're not that bad" my whole life, I continued to hear that after being diagnosed with leukemia — which some called "the best" cancer to have.

CAR T-cell therapy positively benefitted patients with patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Fit patients with chronic lymphocytic leukemia treated with Venclexta and Gazyva, regardless of the use of Imbruvica, experienced improvements in progression-free survival and were more likely to obtain undetectable minimal residual disease.

Patients 65 years and older treated with Venclexta, Imbruvica and Gazyva for CLL had similar rates of progression-free survival compared with those treated with Imbruvica and Gazyva.

Patients with inactive early-stage chronic lymphocytic leukemia may benefit from a wait-and-watch approach compared with immediate treatment with Imbruvica, findings from a phase 3 trial showed.

An ongoing trial is examining Calquence in older or frail patients with chronic lymphocytic leukemia — a group that is typically left out of clinical trials.

Days before I went on vacation, I learned that my blood cancer might have progressed to a more aggressive disease.

Before leaving on vacation, I had to make sure I had enough of my cancer medication to last me through the trip.

Findings from a study demonstrated that patients may develop hypertension, or high blood pressure, as a result of treatment with Imbruvica for CLL, although it may be quickly managed without drug-drug interactions.

An ultrasound revealed a solid mass in my breast that would need further follow-up.

A phase 1/1b trial will examine PRGN-3007 in patients with ROR1-positive hematologic and solid cancers.

Here’s a look back at the cancer drugs that gained FDA approval in the winter of 2023.

Personalized medicine means not only more powerful drugs for cancers, but also more precise mechanisms that target the specific consequence of mutations and other alterations that drive cancer cell growth, sparing normal cells.

Bruton tyrosine kinase inhibitors have changed the space for treating patients with CLL or SLL, with more on the way to potentially address drug resistance.

When I share my story and use my cancer diagnosis to help others, cancer becomes a “club” that’s a little more inviting.

Laughter helped me get through many of cancer’s uncomfortable situations, including a recent MRI, where I was laughing despite not being able to move.

The TRANSCNED CLL 004 trial met its primary endpoint of complete responses with the CAR-T cell therapy Breyanzi in patients with relapsed or refractory CLL or SLL.

Two experts explain what patients need to know about the recent approval of Brukinsa for patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

The Food and Drug Administration approved Brukinsa for patients with chronic lymphocytic leukemia or small lymphocytic leukemia.

Life looks a bit different after my cancer diagnosis and the COVID-19 pandemic, making me even more grateful for the people in my life.

When cancer entered our life, fear was a constant. However, we tried to live as joyously as possible between check-ups.

Progression-free survival and overall response rates greatly improved in patients with CLL/SLL treated with Brukinsa compared with Imbruvica.

Patients with chronic lymphocytic leukemia tended to switch to another regimen or intensify their Calquence treatment quicker than those given Imbruvica, study results showed.